Deep Dive
来自我们记者的行业洞察
Biotech IPOs: The Industry's Lifeline, Tracking Performance and Trends
Initial public offerings (IPOs) are the core engine driving the biotech industry. Over the past decade, Wall Street has opened its doors to biotech companies, peaking in 2021 when over 100 companies went public, raising nearly $15 billion. Since then, the market has sharply declined, with IPO activity stalling in 2022 and only 11 drugmakers pricing their offerings in 2023. Today, the path to the public market for emerging biotech companies is more rugged. BioPharma Dive uses its database to continuously track which companies successfully go public, create value, or fail, as well as which types of companies yield the best returns and who their investors are.
Spinal Muscular Atrophy: From No Treatment to Three Options, Patients Face Difficult Choices
Over the past five years, three therapies for spinal muscular atrophy (SMA) have been approved sequentially, completely transforming the treatment outlook for this rare neuromuscular disease. From one-time gene therapy to intrathecal injections and oral medications requiring long-term maintenance, each option has its own advantages and disadvantages in terms of efficacy, convenience, and cost. However, due to the lack of directly comparative clinical data, patients and physicians still face many uncertainties regarding 'how to choose.'
Analysis of CEO and Employee Compensation at Biotechnology and Pharmaceutical Companies
A BioPharma Dive analysis of 231 publicly traded biotechnology and pharmaceutical companies shows that CEO compensation grew significantly between 2017 and 2019, with a median increase of about 50%, far outpacing employee compensation growth. The pay gap is particularly pronounced at large pharmaceutical companies, but biotechnology companies, due to higher employee compensation, have a relatively moderate overall gap.
Can Relay Therapeutics, Aiming to Revolutionize Drug Design, Continue the Path Pioneered by Vertex?
Relay Therapeutics, a five-year-old biotechnology company, has raised nearly $1 billion. Its core method involves simulating protein motion to distinguish similar proteins and design better drugs. This year, the company publicly disclosed its first three investigational drugs, with RLY-4008 showing significantly better selectivity for FGFR2 in preclinical studies compared to existing drugs. However, experts caution that the importance of protein motion has not yet been proven, and the industry's failure rate remains high.
Can Vaccines End the COVID-19 Pandemic? Global Distribution Faces Challenges
Progress has been made in COVID-19 vaccine development, but global production capacity is concentrated in a few wealthy countries, sparking concerns about 'vaccine nationalism.' Companies like Moderna and Pfizer have pledged to expand supply, the US government insists on putting its own country first, and international organizations call for multilateral coordination. This article analyzes production capacity distribution, political maneuvering, and distribution challenges, pointing out that equitable vaccine access still requires international cooperation.
COVID-19 Vaccine Rollout Accelerates: A Panoramic Tracking of the R&D Pipeline
Over the past 18 months, scientists, pharmaceutical companies, and governments have advanced COVID-19 vaccine development and production at an unprecedented pace. This article reviews the progress, efficacy data, and supply landscape of major global candidate vaccines as of November 24, 2021.
As biotech venture capital warms up, the pandemic strikes suddenly
In the past few years, biotech startups have enjoyed the best period for venture capital. However, the outbreak of the COVID-19 pandemic has brought new uncertainties to investors and investment directions. This article explores how the pandemic has affected the venture capital landscape in the biotech sector.
The Race in Antibody Drug Development: The Next Breakthrough in COVID-19 Treatment?
Although vaccines are seen as the ultimate means to end the COVID-19 pandemic, their development and distribution still require time. Multiple biopharmaceutical companies are accelerating the development of monoclonal antibody drugs, aiming to provide short-term protection or treatment options before vaccines are launched. This article reviews the development strategies, potential application scenarios, and challenges faced by companies such as Regeneron, Eli Lilly, Amgen, and Vir.